, Volume 36, Issue 6, pp 773–783 | Cite as

Current Status of β-Blocking Drugs in the Treatment of Anxiety Disorders

  • Peter Tyrer
Review Article


β-Adrenoceptor blocking drugs have been used for the treatment of acute stress reactions, adjustment disorders, generalised anxiety, panic disorder and agoraphobia. In general they are effective in these disorders if somatic or autonomic symptoms are prominent but not extreme in degree. Thus, they are of more value for the relatively mild tremor of the anxious violinist in public performance than in the severe shaking noticed during a panic attack. It is most likely that β-blockers act primarily by blocking peripheral adrenergic β-receptors; symptoms that are mediated through β-stimulation, such as tremor and palpitations, are helped most. Improvement is noted within 1 to 2 hours and with relatively low doses (e.g. propranolol 40 mg/day). Some recent studies, however, have suggested that when longer treatment using higher doses (e.g. propranolol 160 mg/day) is given, improvement in other forms of anxiety is noted after several weeks of treatment, β-blocking drugs are useful adjuncts to existing treatments for anxiety and are likely to enjoy wider use now that benzodiazepines are being avoided due to their dependence risks.


Propranolol Anxiety Disorder Social Phobia Panic Disorder Essential Tremor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R), 3rd ed., American Psychiatric Association, Washington, 1987Google Scholar
  2. Bonn JA, Turner P. D-Propranolol and anxiety. Lancet 1: 1355–1356, 1971PubMedCrossRefGoogle Scholar
  3. Bonn JA, Turner P, Hicks DC. Beta-adrenergic-receptor blockade with practolol in treatment of anxiety. Lancet 1: 814–815, 1972PubMedCrossRefGoogle Scholar
  4. Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockade and beta stimulation on stage fright. American Journal of Medicine 72: 88–94, 1982PubMedCrossRefGoogle Scholar
  5. Brewer C. Beneficial effect of beta-adrenergic blocking agents on ‘exam nerves’. Lancet 2: 435, 1972PubMedCrossRefGoogle Scholar
  6. Burrows GD, Davies B, Fail L, Poynton S, Stevenson H. A placebo controlled trial of diazepam and oxprenolol for anxiety. Psychopharmacology 50: 177–179, 1976PubMedCrossRefGoogle Scholar
  7. Cleghorn JM, Peterfry G, Pinter EJ, Pattee CJ. Verbal anxiety and the beta-adrenergic receptors: a facilitating mechanism? Journal of Nervous and Mental Disease 151: 266–272, 1970PubMedCrossRefGoogle Scholar
  8. Eliasch H, Lager CG, Norrback K, Rosen A, Scott H. The beta-adrenergic receptor blockade modification of the systemic haemodynamic effects of link trainer simulated flight. Forsvarmedicin 3 (Suppl. 2): 120–129, 1967Google Scholar
  9. Falloon IR, Lloyd GG, Harpin R. The treatment of social phobia: real-life rehearsal with nonprofessional therapists. Journal of Nervous and Mental Disease 169: 180–184, 1981PubMedCrossRefGoogle Scholar
  10. Frohlich ED, Dunstan HP, Page IH. Hyperdynamic beta-adrenergic circulatory state. Archives of Internal Medicine 117: 614–619, 1966PubMedCrossRefGoogle Scholar
  11. Gorman JM, Gorman LK. Drug treatment of social phobias. Journal of Affective Disorders 13: 183–192, 1987PubMedCrossRefGoogle Scholar
  12. Gorman JM, Liebowitz MR, Fyer AJ, Campeas R, Klein DF. Treatment of social phobia with atenolol. Journal of Clinical Psychopharmacology 5: 298–301, 1985PubMedCrossRefGoogle Scholar
  13. Gottschalk LA, Stone WN, Gleser GC. Peripheral versus central mechanisms accounting for anti-anxiety effect of propranolol. Psychosomatic Medicine 36: 47–56, 1974PubMedGoogle Scholar
  14. Granville-Grossman KL, Turner P. The effect of propranolol on anxiety. Lancet 1: 788–790, 1966PubMedCrossRefGoogle Scholar
  15. Hafner J, Milton F. The influence of propranolol on the exposure in vivo of agoraphobics. Psychological Medicine 7: 417–425, 1977CrossRefGoogle Scholar
  16. Hallstrom C, Treasaden I, Edwards JG, Lader M. Diazepam, propranolol and their combination in the management of chronic anxiety. British Journal of Psychiatry 139: 417–421, 1981PubMedCrossRefGoogle Scholar
  17. Hartley LR, Ungapen S, Davie I, Spencer DJ. The effect of beta adrenergic blocking drugs on speakers’ performance and memory. British Journal of Psychiatry 142: 512–517, 1983PubMedCrossRefGoogle Scholar
  18. Holmberg G, Levi L, Mathe A, Rosen A, Scott H. Plasma cate-cholamines and the effects of adrenergic beta-receptor blockade on cardiovascular reactions and subjective feelings during emotional stress. Forsvarmedicin 3 (Suppl. 2): 201–221, 1967Google Scholar
  19. Hunninghake DB, Azarnoff DL, Waxman D. Drug inhibition of catecholamine-induced metabolic effects in humans. Annäls of the New York Academy of Sciences 139: 971–981, 1967PubMedCrossRefGoogle Scholar
  20. James IM. Practical aspects of the use of beta-blockers in anxiety states: situational anxiety. Postgraduate Medical Journal 60 (Suppl. 2): 19–25, 1984PubMedGoogle Scholar
  21. James IM, Burgoyne W, Savage IT. Effect of pindolol on stress-related disturbances of musical performances: preliminary communication. Journal of the Royal Society of Medicine 76: 194–196, 1983PubMedGoogle Scholar
  22. James IM, Griffiths DNW, Pierson RM, Newbury P. Effect of oxprenolol on stage-fright in musicians. Lancet 2: 952–954, 1977PubMedCrossRefGoogle Scholar
  23. James IM, Temple-Savage I. Beneficial effects of nadolol on anxiety induced disturbance of performance in musicians: a comparison with diazepam and placebo. American Heart Journal 108: 1150–1155, 1984PubMedCrossRefGoogle Scholar
  24. Jefferson D, Jenner P, Marsden CD. Beta-adrenoceptor antagonists in essential tremor. Journal of Neurology, Neurosurgery and Psychiatry 42: 904–909, 1979CrossRefGoogle Scholar
  25. Johnson G, Singh B, Leeman M. Controlled evaluation of the beta-adrenoreceptor blocking drug oxprenolol in anxiety. Medical Journal of Australia 1: 909–912, 1976PubMedGoogle Scholar
  26. Kabes J, Dostal T. Clinical effects of beta-adrenergic blockers in psychiatry (propranolol, trimepranol). Activitas Nervosa Superior 17: 279–280, 1975PubMedGoogle Scholar
  27. Kathol RG, Noyes R, Slymen DJ, Crowe RB, Clancy J, et al. Propranolol in chronic anxiety disorders: a controlled study. Archives of General Psychiatry 37: 1361–1365, 1980PubMedCrossRefGoogle Scholar
  28. Kellner R, Collins AC, Shulman RS, Pathak D. Short-term anti-anxiety effects of propranolol HC1. Journal of Clinical Pharmacology 14: 301–304, 1974PubMedGoogle Scholar
  29. Kolb LC, Bums BC, Griffiths S. Propranolol and clonidine in the treatment of post-traumatic stress disorders of war. In van der Kolk BA (Ed.) Post-traumatic stress disorder psychological and biological sequelae, American Psychiatric Press, Washington, 1984Google Scholar
  30. Krishnan G. Oxprenolol in the treatment of examination nerves. Scottish Medical Journal 20: 288–289, 1975PubMedGoogle Scholar
  31. Liden S, Gottfriess CG. Beta-blocking agents in the treatment of catecholamine-induced symptoms in musicians. Lancet 2: 529, 1974PubMedCrossRefGoogle Scholar
  32. MacDonald AG, Ingram CG, McNeill RS. The effect of propranolol on airway resistance. British Journal of Anaesthesia 39: 919–926, 1967PubMedCrossRefGoogle Scholar
  33. Marks I. Agoraphobia, panic disorder and related conditions in the DSM-III-B and ICD-10. Journal of Psychopharmacology 1:6–12, 1987PubMedCrossRefGoogle Scholar
  34. Marsden CW. Propranolol in neurocirculatory asthenia and anxiety. Postgraduate Medical Journal (Suppl. 47): 100–103,1971Google Scholar
  35. Marsden CD, Foley TH, Owen DAL, McAllister RG. Peripheral beta-adrenergic receptors concerned with tremor. Clinical Science 33: 53–56, 1967PubMedGoogle Scholar
  36. McMillin WP. Oxprenolol in the treatment of anxiety due to environmental stress. American Journal of Psychiatry 132: 965–968, 1975PubMedGoogle Scholar
  37. Munjack DJ, Rebal R, Shaner R, Staples F, Braun R, et al. Imipramine versus propranolol for the treatment of panic attacks: a pilot study. Comprehensive Psychiatry 26: 80–89, 1985PubMedCrossRefGoogle Scholar
  38. Neftel KA, Adler RH, Kappell L, Rossi M, Dolder M, et al. Stage fright in musicians: a model illustrating the effect of beta-blockers. Psychosomatic Medicine 44: 461 -469, 1982PubMedGoogle Scholar
  39. Nordenfelt I, Persson S, Redfors A. Effect of a new adrenergic beta-blocking agent, H 56-28, on nervous heat complaints. Acta Medica Scandinavica 184: 465–471, 1968PubMedCrossRefGoogle Scholar
  40. Noyes R, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, et al. Diazepam and propranolol in panic disorder and agoraphobia. Archives of General Psychiatry 41: 287–292, 1984PubMedCrossRefGoogle Scholar
  41. Noyes R, Kathol R, Clancy J, Crowe RR. Antianxiety effects of propranolol: a review of clinical studies. In Klein DF & Rabkin J (Eds) Anxiety: new research and changing concepts, pp. 81–93, Raven Press, New York, 1981Google Scholar
  42. Owen RT, Tyrer P. Benzodiazepine dependence — a review of the evidence. Drugs 25: 385–398, 1983PubMedCrossRefGoogle Scholar
  43. Pitts FN, Allen RE. Beta-adrenergic blockade in the treatment of anxiety. In Mathew RJ (Ed.) Biology of anxiety, pp. 134–161, Brunner/Mazel, New York, 1982Google Scholar
  44. Quality Assurance Project. Treatment outlines for the management of anxiety states. Australian and New Zealand Journal of Psychiatry 19: 138–151, 1985Google Scholar
  45. Ramsey I, Greer S, Bagley C. Propranolol in neurotic and thyrotoxic anxiety. British Journal of Psychiatry 122: 555–560, 1973CrossRefGoogle Scholar
  46. Rickels K, Case GW, Winokur A, Swenson C. Long-term benzodiazepine therapy: benefits and risks. Psychopharmacology Bulletin 20: 608–615, 1984PubMedGoogle Scholar
  47. Seivewright N. Relationship between life events and personality in psychiatric disorder. Stress Medicine 3: 163–168, 1987CrossRefGoogle Scholar
  48. Shehi M, Patterson WM. Treatment of panic attacks with alprazolam and propranolol. American Journal of Psychiatry 141: 900–901, 1984PubMedGoogle Scholar
  49. Silverstone JT. Some new approaches to the treatment of anxiety. Psychopharmacology Bulletin 10: 10–11, 1974Google Scholar
  50. Suzman MM. The use of beta-adrenergic blockade with propranolol in anxiety states. Postgraduate Medical Journal (Suppl. 47): 104–108, 1971Google Scholar
  51. Tanna VT, Pennigroth RP, Woolson RF. Propranolol in the treatment of anxiety neurosis. Comprehensive Psychiatry 18: 319–325, 1977PubMedCrossRefGoogle Scholar
  52. Thyer BA, Hinle J, Curtus GC, Cameron OG, Nesse RM. The comparison of panic disorder and agoraphobia with panic attacks. Comprehensive Psychiatry 26: 208–214, 1985PubMedCrossRefGoogle Scholar
  53. Tyrer P. The role of bodily feelings in anxiety. Oxford University Press, London, 1976Google Scholar
  54. Tyrer PJ. The use of beta-blocking drugs in psychiatry and neurology. Drugs 20: 300–308, 1980PubMedCrossRefGoogle Scholar
  55. Tyrer P. The concept of somatic anxiety. British Journal of Psychiatry 140: 325, 1982PubMedCrossRefGoogle Scholar
  56. Tyrer P. Classification of anxiety disorders: a critique of DSM-III. Journal of Affective Disorders 11: 99–104, 1986PubMedCrossRefGoogle Scholar
  57. Tyrer P. Dependence as a limiting factor in the clinical use of minor tranquillisers. Pharmacology and Therapeutics 36: 173–188, 1988PubMedCrossRefGoogle Scholar
  58. Tyrer P, Casey P, Ferguson B. Personality disorder and mental illness. In Tyrer P (Ed.) Personality disorder: diagnosis, management and course, pp. 93–104, Wright, London, 1988Google Scholar
  59. Tyrer PJ, Lader MH. Effects of beta-adrenergic blockade with sotalol in chronic anxiety. Clinical Pharmacology and Therapeutics 14: 418–426, 1973PubMedGoogle Scholar
  60. Tyrer PJ, Lader MH. Response to propranolol and diazepam in somatic and psychic anxiety. British Medical Journal 2: 14–16, 1974aPubMedCrossRefGoogle Scholar
  61. Tyrer PJ, Lader MH. Physiological responses to propranolol and diazepam in chronic anxiety. British Journal of Clinical Pharmacology 1: 387–390, 1974bPubMedCrossRefGoogle Scholar
  62. Tyrer P, Owen R, Dawling S. Gradual withdrawal of diazepam after long-term therapy. Lancet 1: 1402–1406, 1983PubMedCrossRefGoogle Scholar
  63. Tyrer P, Rutherford D, Huggett T. Benzodiazepine withdrawal symptoms and propranolol. Lancet 1: 520–522, 1981PubMedCrossRefGoogle Scholar
  64. Wheatley D. Comparative effects of propranolol and chlordiazepoxide in anxiety states. British Journal of Psychiatry 115: 1411–1412, 1969PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1988

Authors and Affiliations

  • Peter Tyrer
    • 1
  1. 1.Mapperley HospitalNottinghamEngland

Personalised recommendations